Voyager Therapeutics reported a significant increase in quarterly collaboration revenue and maintained a strong cash position of $201.7 million, which is expected to fund operations into 2028. While the company realized a net loss for the quarter, it was narrower than the previous year's Q4, and the company is preparing for multiple clinical entries in the second half of 2026.

Voyager Therapeutics experienced a drop in collaboration revenue in Q3 2025, resulting in a net loss increase. R&D spending rose to support pipeline programs, while G&A expenses remained stable. The company maintained a strong cash position to support operations into 2028.

Voyager Therapeutics reported a net loss of $31.0 million for the first quarter of 2025, compared to a net loss of $11.3 million in the same period last year. Collaboration revenue decreased to $6.5 million from $19.5 million in Q1 2024, primarily due to reduced revenue from Neurocrine collaboration agreements. The company ended the quarter with a strong cash position of $295 million, providing runway into mid-2027.

Voyager Therapeutics experienced a substantial drop in collaboration revenue in Q4 2024 due to reduced revenue recognition from its Neurocrine and Novartis partnerships. Increased research and development expenses contributed to a net loss of $34.5 million. Despite this, the company maintains a strong cash position and expects its financial runway to last into mid-2027.

Voyager Therapeutics reported increased collaboration revenue and a reduced net loss for the third quarter of 2024. The company's cash position remains strong, providing a runway into 2027.

Voyager Therapeutics reported a net loss of $11.3 million for Q1 2024, primarily due to decreased collaboration revenue compared to the same period in 2023. However, the company announced the clearance of the IND application for VY-TAU01, selection of development candidates for Neurocrine-partnered programs, and a strong cash position of approximately $400 million.

Voyager Therapeutics reported a strong fourth quarter, marked by a significant increase in collaboration revenue primarily due to the Novartis agreement, leading to a net income of $56.4 million. The company's pro-forma cash position as of December 31, 2023, was approximately $431 million, adjusted for the Novartis agreements and public offering.

Voyager Therapeutics reported a net loss of $25.9 million for the third quarter of 2023, with collaboration revenues totaling $4.6 million. The company is advancing its pipeline, including the initiation of GLP toxicology studies for its anti-tau antibody VY-TAU01 and progress in its SOD1 ALS gene therapy program.

Voyager Therapeutics reported a net loss of $22.2 million for Q2 2023, compared to a net loss of $19.1 million for the same period in 2022. Collaboration revenue increased to $4.9 million from $0.7 million year-over-year, driven by collaborations with Neurocrine Biosciences. The company's cash, cash equivalents, and marketable securities totaled $272.7 million as of June 30, 2023.

Voyager Therapeutics reported a net income of $124.0 million for Q1 2023, a significant increase compared to the net loss of $21.3 million for the same period in 2022. This improvement was primarily driven by collaboration revenues of $150.5 million, resulting from strategic collaborations with Neurocrine Biosciences and Novartis.

Voyager Therapeutics reported a net loss of $23.6 million for the fourth quarter of 2022, compared to a net income of $5.7 million for the same period in 2021. The negative collaboration revenue during the fourth quarter of 2022 was due to an increase in the estimate of the total expected cost of Voyager’s research services related to the 2019 collaboration with Neurocrine Biosciences.

Voyager Therapeutics reported a net income of $17.6 million for Q3 2022, a significant increase compared to a net loss of $25.1 million for the same period in 2021. This was primarily driven by a substantial increase in collaboration revenue, particularly from Pfizer's option exercise to license a novel capsid from Voyager's TRACER platform.

Voyager Therapeutics reported a net loss of $19.1 million for the second quarter of 2022, compared to a net loss of $30.1 million for the same period in 2021. The company's prioritized pipeline focuses on programs with efficient paths to human proof of biology, including GBA1 gene replacement for Parkinson's disease, SOD1 gene silencing for ALS, and a tau antibody program for Alzheimer's disease.

Voyager Therapeutics reported a net loss of $21.3 million for the first quarter of 2022, with collaboration revenue of $0.7 million. The company's cash, cash equivalents, and marketable debt securities totaled $166.8 million as of March 31, 2022, expected to fund operations into 2024. Voyager continued to advance its TRACER capsid discovery platform and pipeline programs, including a license option agreement with Novartis.

Voyager Therapeutics reported collaboration revenue of $28.1 million for the fourth quarter of 2021, compared to $6.5 million for the same period in 2020, with a net income of $5.7 million for the fourth quarter of 2021, compared to a net loss of $15.9 million for the same period of 2020.

Voyager Therapeutics reported a net loss of $25.1 million for the third quarter of 2021, a significant change from the net income of $85.6 million reported for the same period in 2020. The decrease in collaboration revenue was largely due to a reduction of revenue related to research services and cost reimbursements from the collaborations with Neurocrine and AbbVie.